Back ground:The genetic and molecular profiles of triple negative breast carcinoma (TNBC) are elucidated, multiple therapeutic targets have been produced. TNBC with less than 1% androgen receptor (AR) expression may respond to enzalutamide with greater response association in higher levels. A metronomic dose of capecitabine and docetaxel are effective developed drugs for angiogenic process inhibition. Purpose: The study aimed todemonstrate the treatment outcome of triple-negative breast cancer patients in correlation to their clinicopathological features. Materials and Methods:A retrospective cohort study of 80 TNBC patients was conducted. The patients underwent proper observation with thereporting of their treatment and follow-up data. Patients with a metastatic disease, neoadjuvant chemotherapy, follow-up drop or data shortage were excluded from the survival analysis. Results:The study results revealed a significant association between negative androgen expression and younger age ≤35 years, premenopausalstatus, higher grade, extracapsular extension, lymphovascular invasion, Ki 67, and CA15-3 (p=0.003, 0.02, <0.001, 0.001, 0.027, 0.005, 0.009respectively). The three-year overall survival (OS) in patients who received bicalutamide was better than those patients who received capecitabineor docetaxel but of no significance (p=0.46). The three-year disease free survival (DFS) was significantly better in the bicalutamide arm versusthe other two groups (p=0.012). Conclusions:We concluded that extended adjuvant antiandrogen such as bicalutamide and metronomic capecitabine are well tolerated withaccepted compliance and affordability compared to docetaxel and are warranted for problem-solving and better DFS and OS in some TNBCpatients.